- Lantern Pharma Inc. is a clinical-stage oncology biotechnology company utilizing AI, machine learning, and genomic data to develop, streamline, rescue, and revitalize small-molecule drugs (oftentimes abandoned or failed) for targeted oncology patients.
- Lantern's pipeline consists of four therapeutic programs (2 clinical-stage) precisely targeting a variety of oncological indications to specific stratified patient sub-populations typically representing 14.5% of their original indicated patients.
- Lantern is financially quite stable (2-3 years of funding) for a non-revenue producing biotech and clearly highlights fiscal responsibility most likely stemming from the CEO's background in corporate finance and strategy.
- Lantern is expected to have several upcoming catalysts with the most impactful being the 2H 2021's LP-300 Phase 2 trial launch and its 2022 interim data readout.
- In summary, the author projects Lantern Pharma Inc. as a medium-term promising "buy".
For further details see:
Lantern: Changing The Cost-Curve, Changing The Risk, AI-Biotech Unlocks New Value